Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-label Study of ABI-009 (Nab-Rapamycin) in Patients With Recurrent High-grade Glioma and Patients With Newly Diagnosed Glioblastoma
Conditions
Interventions
nab-sirolimus
nab-sirolimus + temozolomide
+4 more
Locations
3
United States
St. Joseph Heritage Healthcare
Fullerton, California, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
John Wayne Cancer Institute
Santa Monica, California, United States
Start Date
August 1, 2018
Primary Completion Date
August 26, 2022
Completion Date
August 26, 2022
Last Updated
November 7, 2023
Lead Sponsor
Aadi Bioscience, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions